340 related articles for article (PubMed ID: 25982915)
1. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
Di Bella S; Nisii C; Petrosillo N
Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
[TBL] [Abstract][Full Text] [Related]
2. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report.
Knafl D; Winhofer Y; Lötsch F; Weisshaar S; Steininger C; Burgmann H; Thalhammer F
J Hosp Infect; 2016 Mar; 92(3):296-8. PubMed ID: 26810610
[No Abstract] [Full Text] [Related]
4. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients.
Metan G; Türe Z; Kaynar L; Berk E; Gürsoy Ş; Alp E; Kılıç H; Çetin M
J Chemother; 2015; 27(6):354-7. PubMed ID: 25407220
[No Abstract] [Full Text] [Related]
6. Tigecycline for severe Clostridium difficile infection.
Thomas A; Khan F; Uddin N; Wallace MR
Int J Infect Dis; 2014 Sep; 26():171-2. PubMed ID: 25064460
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
8. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
9. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Herpers BL; Vlaminckx B; Burkhardt O; Blom H; Biemond-Moeniralam HS; Hornef M; Welte T; Kuijper EJ
Clin Infect Dis; 2009 Jun; 48(12):1732-5. PubMed ID: 19435431
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
11. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
[TBL] [Abstract][Full Text] [Related]
12. The potential for emerging therapeutic options for Clostridium difficile infection.
Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline exhibits inhibitory activity against Clostridium difficile in the intestinal tract of hospitalised patients.
Kundrapu S; Hurless K; Sunkesula VC; Tomas M; Donskey CJ
Int J Antimicrob Agents; 2015 Apr; 45(4):424-6. PubMed ID: 25623897
[TBL] [Abstract][Full Text] [Related]
14. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence.
Kechagias KS; Chorepsima S; Triarides NA; Falagas ME
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1053-1058. PubMed ID: 31927652
[TBL] [Abstract][Full Text] [Related]
16. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Wilcox MH
Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
[TBL] [Abstract][Full Text] [Related]
17. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole.
Lu CL; Liu CY; Liao CH; Huang YT; Wang HP; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):311-2. PubMed ID: 20045292
[No Abstract] [Full Text] [Related]
18. Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Pelemis M; Delic D; Prostran M; Milosevic I
J Infect Dev Ctries; 2015 Oct; 9(10):1062-7. PubMed ID: 26517480
[TBL] [Abstract][Full Text] [Related]
19. [Case series of Clostridium difficile NAP1/027/BI with novels treatments].
Pérez-Topete SE; Miranda-Aquino T; Ayala-Gaytan JJ
Rev Med Inst Mex Seguro Soc; 2017; 55(5):654-659. PubMed ID: 29193949
[TBL] [Abstract][Full Text] [Related]
20. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.
Debast SB; Bauer MP; Kuijper EJ;
Clin Microbiol Infect; 2014 Mar; 20 Suppl 2():1-26. PubMed ID: 24118601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
